|The following article is part of conference coverage from the 2018 Genitourinary Cancers Symposium in San Francisco. Renal and Urology News’ staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from GU 2018.|
SAN FRANCISCO—Cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) with papillary histology may improve survival, investigators reported at the 2018 Genitourinary Cancers Symposium.
Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) database, Jeffrey Graham, MD, of the Tom Baker Cancer Centre at the University of Calgary in Alberta, Canada, and colleagues studied 353 patients with papillary mRCC. The 244 patients who underwent CN had a significantly longer median overall survival compared with the 109 patients who did not (16.3 vs 8.6 months). After adjusting for individual IMDC risk, CN was associated with a significant 38% decreased risk of death.
Patients in the CN group were significantly younger than those in the no-CN group (59 vs 67 years), and they had better Karnofsky Performance scores (KPS): 19% of the CN group had a KPS less than 80 compared with 31% of the no-CN group.
“Overall, it appears cytoreductive nephrectomy is associated with improved survival in metastatic papillary renal cell carcinoma, even when controlling for prognostic imbalances,” the authors concluded in a poster presentation.
Similar to the population of patients with clear-cell RCC, “appropriate patient selection will be critical, and subgroup analysis of the individual IMDC risk factors may be helpful.”
Visit Renal and Urology News‘ conference section for continuous coverage from GU 2018.
Graham J, Wells C, Donskov F, et al. Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Presented at the 2018 Genitourinary Cancers Symposium held in San Francisco Feb. 8-10. Abstract 581.